Evidence map›Paper›PMID 39136200›Full record

Trial reportCancer medicine2024

Initial ribociclib plus endocrine therapy for HR+/HER2- advanced breast cancer in pre- and postmenopausal Chinese women: Primary results from a phase 2 randomized study.

Zhimin Shao, Zhongsheng Tong, Qiang Liu, Wei Li, Li Cai, Kunwei Shen, Huiping Li, Chuan Wang, Jin Yang, Zhenchuan Song and 12 more

Erratum issuedAbstract readRandomized Controlled TrialClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Zhimin ShaoFudan University Shanghai Cancer Center, Shanghai, China.ORCID 0009-0009-1824-455X
Zhongsheng TongTianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Qiang LiuSun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Wei LiThe First Bethune Hospital of Jilin University, Changchun, China.ORCID 0000-0002-9479-028X
Li CaiHarbin Medical University Cancer Hospital, Harbin, China.
Kunwei ShenRuiJin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Huiping LiDepartment of Breast Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China.ORCID 0000-0002-3331-647X
Chuan WangAffiliated Union Hospital of Fujian Medical University, Fuzhou, China.
Jin YangThe 1st Affiliated Hospital of Xi'an Jiaotong University, Xi'An, China.
Zhenchuan SongFourth Hospital of Hebei Medical University, Shijiazhuang, China.
Shui WangJiang Su Province RenMin Hospital, Nanjing, China.ORCID 0000-0001-8878-9162
Ting LuoWest China Hospital, Sichuan University, Chengdu, China.
Wenhe ZhaoSir Run Run Shaw Hospital/Zhejing University School of Medicine, Hangzhou, China.
Haibo WangThe Affiliated Hospital of Qingdao University, Qingdao, China.
Yueyin PanAnhui Provincial Hospital, Hefei, China.
Jianyun NieYunnan Provincial Cancer Hospital, Kunming, China.
Xiaohua ZengChongqing Cancer Hospital, Chongqing, China.ORCID 0000-0001-5810-8055
Yanqing BaiNovartis Global Drug Development, Beijing, China.
Wendy ChiangNovartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Valeria GuarnacciaNovartis Pharmaceuticals Corporation, Basel, Switzerland.
Yu BiNovartis Global Drug Development, Beijing, China.
Binghe XuNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Funding

Novartis Pharmaceuticals Corporation
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AminopyridinesAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesLetrozolePostmenopausePurinesReceptors, EstrogenAdultAgedAromatase InhibitorsChinaEast Asian PeopleFemaleGoserelinHumansAminopyridinesAromatase InhibitorsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesGoserelinLetrozolePurinesReceptors, EstrogenReceptors, Progesteroneribociclib

Identifiers

PMID39136200
PMCPMC11320080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.